Acuamark Diagnostics
Previously, Dr. Flom was EVP and Chief Regulatory Officer at Cepheid (acquired by Danaher NYSE:DHR) where he had worldwide responsibility for development, implementation and management of Cepheid’s clinical and regulatory programs. Earlier, he served as Sr. Director, Clinical Affairs and Regulatory Submissions at Abbott Molecular Diagnostics, at Baxter as Director of Clinical Affairs, at Oncor and at Boehringer Mannheim. Throughout his career, Dr. Flom has led for over 30 products through regulatory filings and registration in the US and numerous international product registrations.
This person is not in the org chart
This person is not in any offices
Acuamark Diagnostics
Acuamark Diagnostics (formerly iCareDx) develops technology which allows for highly accurate screening of blood to detect cancer markers at the early cancer stages, before the cancer becomes untreatable.